HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a ...

HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (BPTH),, a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio ...

HOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop ...

Bio-Path says the first patient treated with a higher dose in Phase 1/1b study of BP1001-A has shown tumor regression and stable disease. Bio-Path reports its second-quarter financial results last ...

HOUSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio ...

Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher Monday after the company announced the presentation of interim results from its Phase 2 study of prexigebersen (BP1001) in combination ...

Bio-Path Holdings, Inc. has announced a positive outlook for 2025, building on advancements made in 2024 in their clinical development pipeline, which includes targeted nucleic acid drugs for cancer ...

Bio-Path Holdings, Inc. has announced significant progress with its drug BP1001-A, which has shown potential as a treatment for obesity and Type 2 diabetes in recent preclinical studies. The research ...

Turnaround to restart late Phase 2 trial targeting leukemia. Company mulling offers for licenses, partnerships, or sale of intellectual property and assets. Bio-Path Holdings, Inc. (OTCMKTS:BPTH) I ...

HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a ...